Parker-Hannifin Corp (PH) Stock News

Vanguard's VHT and State Street's XPH offer different approaches to healthcare investing. VHT provides broad sector exposure with lower costs (0.09% expense ratio) and higher dividend yield (1.5%), making it ideal for long-term investors. XPH focuses on pharmaceuticals with higher volatility but stronger 1-year returns (57.2% vs 29.3%), appealing to growth-oriented investors willing to accept greater risk.

Rosen Law Firm reminds investors of Park Ha Biological Technology Co., Ltd. (NASDAQ: PHH, BYAH) of the September 28, 2026 lead plaintiff deadline for a securities class action lawsuit. The lawsuit alleges that defendants made materially false statements and failed to disclose that Park Ha was subject to a fraudulent stock promotion scheme involving social media misinformation, artificially low public float, and manipulated trading activity.

Rosen Law Firm reminds investors in Park Ha Biological Technology Co., Ltd. (NASDAQ: PHH, BYAH) who purchased securities between December 27, 2024 and July 8, 2025 of the September 28, 2026 deadline to become lead plaintiffs in an ongoing securities class action. The lawsuit alleges the company made false statements and failed to disclose involvement in stock manipulation schemes, artificially low public float during IPO, and misleading positive statements about business operations.

Phreesia reported Q3 2026 earnings of $0.03 per share, missing consensus estimates of $0.11 by 72.73%, though revenues slightly missed expectations at $129.46M. The stock has underperformed the S&P 500 by 41.5% year-to-date. With a Zacks Rank #3 (Hold) rating and mixed estimate revisions, the stock is expected to perform in line with the market near-term.

Rosen Law Firm is seeking lead plaintiffs for securities class action lawsuits against Park Ha Biological Technology Co., Ltd. and other companies. The firm alleges that Park Ha made materially false statements and failed to disclose a fraudulent stock promotion scheme involving social media misinformation, artificially low public float, and manipulated trading activity during the class period of December 27, 2024 to July 8, 2025. The lead plaintiff deadline is September 28, 2026.

RSPH, an equal-weight healthcare ETF launched in 2006, has gained 17.92% year-to-date and 29.15% over the past year as of August 31, 2026. With $826.52 million in assets and a 0.40% expense ratio, it offers diversified exposure to 63 healthcare holdings. However, cheaper alternatives like VHT (0.09% expense ratio) and XLV (0.08% expense ratio) may be more suitable for cost-conscious investors seeking lower-risk options.

PulteGroup (PHM) closed down 2.52% and is expected to report lower earnings and revenue compared to the prior year. The company has a Zacks Rank of #3 (Hold) with a Forward P/E ratio of 12.85, trading at a discount to its industry average. Consensus estimates project full-year EPS of $10.12 (down 11.54%) and revenue of $16.4 billion (down 5.29%).

A class action lawsuit has been filed against ARS Pharmaceuticals (NYSE:SPRY) for allegedly providing misleading statements about expanded insurance coverage for its epinephrine nasal spray product 'neffy' with CVS Caremark. The company reportedly expressed confidence that coverage would begin July 1, 2026, while failing to disclose risks of delays that would impact summer and back-to-school seasons. Investors who purchased ARS securities between March 9 and June 24, 2026 can apply to be lead plaintiff by October 5, 2026.

Parker-Hannifin (PH) is showing bullish technical indicators after crossing above its 20-day moving average and reaching a key support level. The stock has gained 9.3% over the past four weeks and has received 9 positive earnings estimate revisions with no downward revisions, suggesting potential for further gains.

Amphenol (APH) is displaying bullish technical indicators after breaking above its 50-day moving average and reaching key support levels. The stock has gained 7.3% over the past four weeks and holds a Zacks Rank #2 (Buy) rating. Positive earnings estimate revisions, with no downward revisions in the past two months and five upward revisions, further support the bullish outlook.

Rosen Law Firm has filed a class action lawsuit on behalf of investors in Park Ha Biological Technology Co., Ltd. (NASDAQ: PHH, BYAH) for the period between December 27, 2024 and July 8, 2025. The lawsuit alleges that defendants made materially false statements and failed to disclose that Park Ha was subject to a fraudulent stock promotion scheme involving social media misinformation, impersonated financial professionals, and artificially manipulated trading activity. The firm is seeking investors who purchased securities during the class period to join the action, with a lead plaintiff deadline of September 28, 2026.

Rosen Law Firm has filed class action lawsuits against Park Ha Biological Technology Co., Ltd. (NASDAQ: PHH, BYAH) on behalf of investors who purchased securities between December 27, 2024 and July 8, 2025. The lawsuit alleges that defendants made materially false statements and failed to disclose a fraudulent stock promotion scheme involving social media misinformation, artificially low public float, and manipulated trading activity. The deadline to serve as lead plaintiff is September 28, 2026.

Rosen Law Firm has filed class action lawsuits against Park Ha Biological Technology Co., Ltd. (PHH, BYAH) for securities fraud involving false statements and undisclosed fraudulent stock promotion schemes during December 2024-July 2025. A separate lawsuit targets GRAIL, Inc. (GRAL) with an August 4, 2026 deadline for investors to secure counsel. Both cases allege material misstatements and failure to disclose adverse facts affecting stock prices.

Law firm Kirby McInerney LLP is investigating potential securities fraud claims against Alnylam Pharmaceuticals following the company's announcement on July 30, 2026, that it lowered TTR product sales guidance by approximately $200 million due to normalization of growth in the ATTR-CM market after satisfying pent-up demand. The stock fell 28% ($81.14 per share) to $205.48 on the news.

LEPAS, a mid-to-premium NEV brand under Chery Auto, has launched the LEPAS L8 PHEV to global markets. The vehicle features the LEPAS Super Hybrid system with 45.79% thermal efficiency, 1,300km driving range, and ultra-low fuel consumption of 2.38L/100km. It includes Level 2 ADAS with 540° panoramic imaging and comprehensive safety features including 10 airbags and IP68/IPX9K battery protection.

LEPAS, a mid-to-premium NEV brand under Chery Auto, has launched the LEPAS L8 PHEV globally. The vehicle features the LEPAS Super Hybrid system with 45.79% thermal efficiency, achieving 2.38L/100km fuel consumption and 1,300km range. It incorporates Leopard Aesthetics design philosophy, Level 2 ADAS technology, and comprehensive safety features including 10 airbags and IP68/IPX9K battery protection.

LEPAS, Chery Auto's mid-to-premium NEV brand, unveiled the LEPAS L8 PHEV for global markets. The vehicle features advanced hybrid technology with 45.79% thermal efficiency, 2.38 L/100km fuel consumption, and 1,300km total range. It incorporates 'Leopard Aesthetics' design philosophy, Level 2 ADAS with 540° panoramic vision, and comprehensive safety features including triple-protection battery system.

LEPAS, Chery Auto's mid-to-premium NEV brand, has launched the LEPAS L8 PHEV globally. The vehicle features the LEPAS Super Hybrid System with a 45.79% thermal efficiency, combined fuel consumption of 2.38 l/100km, and a total range of up to 1,300 kilometers. It includes advanced safety features with Level 2 ADAS and distinctive 'Leopard Aesthetics' design language.

LEPAS, Chery Auto's mid-to-premium NEV brand, has launched the LEPAS L8 PHEV globally, featuring advanced hybrid technology with 45.79% thermal efficiency, ultra-low fuel consumption of 2.38L/100km, and up to 1,300km range. The vehicle combines 'Leopard Aesthetic' design philosophy with Level 2 ADAS safety features and premium interior amenities.

LEPAS, a mid-to-premium NEV brand under Chery Auto, has launched the LEPAS L8 PHEV globally. The vehicle features advanced hybrid technology with 45.79% thermal efficiency, a combined fuel consumption of 2.38L/100km, and a range of up to 1,300km. It includes comprehensive safety features with Level 2 ADAS, 10 airbags, and intelligent driver assistance systems.

LEPAS, a mid-to-premium NEV brand under Chery Auto, unveiled the LEPAS L8 PHEV globally, featuring advanced hybrid technology with 45.79% thermal efficiency, 2.38L/100km fuel consumption, and up to 1,300km range. The vehicle combines 'Leopard Aesthetics' design philosophy with Level 2 ADAS and comprehensive safety features, targeting consumers seeking intelligent and elegant mobility solutions.

LEPAS, a mid-to-premium new energy vehicle brand under Chery Auto, officially launched the LEPAS L8 PHEV to global markets. The vehicle features advanced hybrid technology with 45.79% thermal efficiency, 97.6% transmission efficiency, achieving 2.38L/100km fuel consumption and 1300km NEDC range. It incorporates 'Leopard Aesthetic' design philosophy, L2-level autonomous driving assistance, comprehensive safety features including 10 airbags and triple battery protection, and premium interior amenities.

LEPAS, Chery Auto's mid-to-premium NEV brand, has launched the LEPAS L8 PHEV globally. The vehicle features the LEPAS Super Hybrid system with 45.79% thermal efficiency, achieving 2.38 L/100km fuel consumption and 1,300km range. It includes Level 2 ADAS, distinctive 'Leopard Aesthetics' design, and comprehensive safety features including a cage-type body and triple-level battery protection.

Chery Auto's premium NEV brand LEPAS has launched the L8 PHEV globally, featuring advanced hybrid technology, intelligent driving functions, and distinctive 'Leopard Aesthetics' design. The vehicle achieves 45.79% thermal efficiency, 100km fuel consumption of 2.38L, and up to 1,300km combined range with Level 2 ADAS and comprehensive safety systems.

ALPHEA, a platform building infrastructure for AI agents, has secured $5 million in strategic funding from investors including MH Ventures, IBC Ventures, Titan Ventures, and Becker Ventures. The funding will accelerate product development and expand ALPHEA's global node ecosystem, enabling AI agents to run, collaborate, store data, and settle value efficiently in a distributed cloud environment designed specifically for autonomous AI operations.

Pharvaris director Johannes Schikan sold 37,600 shares worth $1.3 million in late June 2026, representing 10.66% of his direct holdings. The sale occurred under a Rule 10b5-1 trading plan following a 96.5% one-year stock price appreciation. Shortly after, the FDA accepted the company's New Drug Application for its lead drug deucrictibant for hereditary angioedema treatment, though the stock has remained relatively flat since the announcement.

ALPHEA, an AI infrastructure platform, has raised $5 million in strategic funding from investors including MH Ventures, IBC Ventures, Titan Ventures, and Becker Ventures. The funding will accelerate development of ALPHEA's AI-native distributed cloud designed specifically for autonomous agents, with plans to expand its global node ecosystem and improve developer tools.

Jyong Biotech reaffirms its strategic focus on global licensing partnerships to address the growing BPH market. The company highlights that the global BPH patient population reached 112.5 million in 2021 and is projected to grow to 150-156 million by 2035, with the market size expected to grow from $13 billion in 2025 to $22-22.6 billion by 2035. Jyong Biotech's lead candidate Botreso® (API-1) has completed four Phase III clinical trials and aims to address unmet medical needs caused by severe side effects of existing treatments.

IXJ and RSPH are two healthcare ETFs with different strategies: IXJ uses cap-weighted global exposure with larger pharmaceutical companies, offering higher dividends (1.47%) and lower volatility (beta 0.52), while RSPH employs equal-weighting of S&P 500 healthcare stocks, providing stronger 1-year returns (21.01% vs 18.29%) but higher risk (beta 0.81). The choice depends on investor goals—IXJ suits conservative/income-focused investors, while RSPH appeals to growth-oriented investors willing to accept volatility.

Rosen Law Firm is reminding Phreesia, Inc. investors who purchased stock between May 8, 2025 and March 30, 2026 of the July 13, 2026 deadline to serve as lead plaintiff in a securities class action. The lawsuit alleges that Phreesia made false statements and concealed material facts regarding slowing demand and weakened pharmaceutical marketing commitments in its Network Solutions segment, resulting in investor damages.